Pernicious anaemia and endocrine glands antibodies.
Hashimoto
adrenal
antibody
autoimmune disease
pernicious anaemia
pituitary
thyroid
Journal
Endokrynologia Polska
ISSN: 2299-8306
Titre abrégé: Endokrynol Pol
Pays: Poland
ID NLM: 0370674
Informations de publication
Date de publication:
2019
2019
Historique:
received:
10
09
2018
accepted:
16
10
2018
revised:
16
10
2018
pubmed:
17
1
2019
medline:
27
8
2019
entrez:
17
1
2019
Statut:
ppublish
Résumé
The aim of the study was to determine the frequency of occurrence of antibodies participating in the development of endocrine diseases in patients with autoimmune haematopoietic disease, thus documenting the potential suitability of specific diagnostic and screening tests. The study group consisted of 124 persons (men and women) with newly diagnosed pernicious anaemia (PA) and a control group (C) of 41 healthy people. Antibodies against: intrinsic factor (IFAb), gastric parietal cells (APCA), thyroid peroxidase (TPOAb), thyroglobulin (TgAb), adrenal cortex (AdrenalAb), and pituitary anterior lobe (PituitaryAb) were determined in the blood. 1. The risk of the presence of antibodies against endocrine glands in patients with PA can be classified in order: TPOAb and/or TgAb - 41.1%, TPOAb - 36.3%, TgAb - 25.0%, TPOAb and TgAb - 20.2%, AdrenalAb - 1.6%, PituitaryAb - 0.8%. 2. TPOAb and/or TgAb (mainly TPOAb) are more frequently present in patients with PA, who have IFAb and/or APCA. This correlation is most evident in patients with simultaneous occurrence of IFAb and APCA. 3. Among patients with PA, the simultaneous presence of antibodies IFAb and/or APCA with TPOAb and/or TgAb antibodies is most likely in women over 45 years of age. 4. In group C, 12% had at least one of two antithyroid antibodies (TgAb twice as often as TPOAb), and 2.4% had both. AdrenalAb and PituitaryAb are not found in healthy persons. In patients with PA, a screening for autoimmune thyroid disease is justified, which should first involve the determination of TPOAb (further TgAb) in the blood. The assessment of antithyroid antibodies should be recommended primarily to patients with PA, who have IFAb and/or APCA, and in particular those with concurrent IFAb and APCA.
Identifiants
pubmed: 30648728
pii: VM/OJS/J/59968
doi: 10.5603/EP.a2018.0086
doi:
Substances chimiques
Antibodies
0
Autoantibodies
0
anti-thyroglobulin
0
Intrinsic Factor
9008-12-2
Thyroglobulin
9010-34-8
Iodide Peroxidase
EC 1.11.1.8
Types de publication
Journal Article
Langues
eng